Drug delivery

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News

#Drug delivery #Drug development #mRNA #Pfizer

Pfizer’s investment that will help speed up new medicine development

Around 85% of Pfizer’s small molecule products pass through Sandwich, Kent, on their journey to market. The work of the Kent site’s team helps millions of patients globally. Brian Henry, Vice President, Drug Product Design, Medicinal Sciences provides Megan Thomas, Drug Discovery World with insight into the scientific learnings of… Read More

#Exclusive Content #News

#Alzheimer's #Data #Drug delivery #Drug design #Exscientia #Pharma

The role of AI in Alzheimer’s drug candidate design

Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More

#Exclusive Content #News

#Antibodies #Complex medicines #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug targets #Life sciences

Financial benefit of complex medicines to UK life sciences

Shaping the UK into an epicentre for complex medicines is a report by the Medicines Discovery Catapult (MDC) in partnership with the CPI, which showcases the potential for the UK in developing complex medicines. The report details the potential medical and economic impact of this field, and how the UK… Read More

#News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Sanofi launches dedicated mRNA vaccines centre

Sanofi will invest approximately €400 million annually in a vaccines mRNA Centre of Excellence. The centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams… Read More

#News

#Automation / robotics #Bioscience #CRO #Drug delivery #Drug development

Video highlights reinvention of western blotting

Aurelia Bioscience, a Nottingham, UK based pre-clinical Contract Research Organisation (CRO) has produced a new video to explain the functioning of WES and JESS – two highly reproducible, capillary based, automated western blot instruments from ProteinSimple: Whilst traditional western blotting typically runs 10-20 samples in three to five… Read More

#News

#AstraZeneca #Biologics / Biotechnology #Clinical trials #Drug delivery #Drug development #Pharma

Chinese/Western partnership to promote indigenous drugs

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the… Read More

#Market Reports #News #Trends & Analysis

#Biologics #Biopharmaceuticals #Drug delivery #Drug development #Events #Process analytical technology

Agilent completes the InfinityLab Bio LC portfolio

Agilent Technologies has launched three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release has been described by Agilent as central to its portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that integrate with Agilent OpenLab and MassHunter software, and… Read More

#News

#Biosciences #Drug delivery #Drug development #Drug discovery

Charnwood Group acquires Aurelia Bioscience

Aurelia Bioscience has announced that after ten years as a standalone biology contract research organisation, the company has been acquired by its collaborator Charnwood Molecular. Co-located in BioCity Nottingham, Aurelia Bioscience and Charnwood Molecular have previously jointly delivered research projects. This acquisition is said to allow both companies to formally… Read More

#News

#Biopharmaceuticals #Drug delivery #Mass spectrometry / NMR

MOBILion System launches high-resolution Ion Mobility instrument

MOBILion is advancing separation science with the commercialisation of High-Resolution Ion Mobility Mass Spectrometry (HRIM-MS) based on Structures for Lossless Ion Manipulation (SLIM). This product addresses characterisation challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides resolution and reproducibility, faster, simpler method development, and greater instrument uptime. This… Read More

#News

#Covid-19 #Drug delivery #Drug development

Corticosteroids could treat Covid-19 complications in children

Corticosteroids may be an effective treatment for children who develop a rare but serious condition after Covid-19 infection. This is the finding of an international study of 614 children, published in the New England Journal of Medicine, led by Imperial College London. All children in the study developed a serious… Read More

#News

#Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Oncology

New oncology research and development collaboration

Genmab and Bolt Biotherapeutics have entered into an oncology research and development collaboration. Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with Bolt’s proprietary Boltbody immune-stimulating antibody conjugate (ISAC) technology platform, with the goal of discovering and developing next-generation, immune-stimulatory, antibody-based conjugate therapeutics for… Read More

#News

#Biotechnology #Biotherapeutics #Drug delivery

Collaboration to develop new therapeutic drug conjugates

Aptamer and PinotBio have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for targeted drug delivery, combining Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker. Optimer therapeutics are optimised aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of… Read More

#News

#Drug delivery #Drug development #Immunology / Virology & Vaccines #mRNA #Vaccines

Samsung Biologics adds mRNA vaccine manufacturing to its services

Samsung Biologics, a CDMO, plans to add mRNA vaccine drug substance (DS) manufacturing capability to its current facility in Songdo, ready for cGMP operations within early 2022. mRNA has been the technology of choice for many Covid-19 vaccines due to its characteristics of safety and fast scalability in manufacturing. “We… Read More

#News

#Clinical trials #Covid-19 #Drug delivery #Drug development #Immunology / Virology & Vaccines #Johnson & Johnson #Vaccines

Janssen single-dose COVID-19 vaccine approved for use in the UK

Johnson & Johnson has announced topline efficacy and safety data from the Phase III ENSEMBLE clinical trial, demonstrating that the investigational single-dose Covid-19 vaccine in development at Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug delivery #Drug development

EMA issues positive scientific opinion on early treatment of Covid-19

GlaxoSmithKline (GSK) and Vir Biotechnology have announced that the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion following the referral of sotrovimab to the CHMP under Article 5(3) of Regulation 726/2004. This relates to the use of sotrovimab for the treatment of… Read More

#Covid-19 #News